Holen Sie sich die Stockscreener-App
1,017.97
3.23%
-34.02
Handel nachbörslich:
1019.15
1.18
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave - The Economic Times
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Laurel Wealth Advisors LLC Lowers Stake in Eli Lilly and Company $LLY - MarketBeat
Finemark National Bank & Trust Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Artisan Partners Limited Partnership Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat
Ibex Wealth Advisors Sells 5,897 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by Power Wealth Management LLC - MarketBeat
Eli Lilly and Company $LLY Position Boosted by Clal Insurance Enterprises Holdings Ltd - MarketBeat
American Century Companies Inc. Acquires 120,905 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Trading Up 2.8% Following Analyst Upgrade - MarketBeat
Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable (NYSE:NVO) - Seeking Alpha
Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle - Fierce Biotech
The New Magnificent Stocks to Own in 2026 - Investing.com
Eli Lilly launches LillyPod, pharma's most powerful supercomputer - R&D World
Is the Market Bullish or Bearish on Eli Lilly and Co? - Benzinga
Lilly’s Olumiant receives positive EU opinion for adolescent alopecia - Investing.com
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Eli Lilly and Company $LLY Position Decreased by MGB Wealth Management LLC - MarketBeat
Handelsbanken Fonder AB Purchases 92,689 Shares of Eli Lilly and Company $LLY - MarketBeat
Generali Investments Management Co LLC Acquires 3,281 Shares of Eli Lilly and Company $LLY - MarketBeat
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Eli Lilly and Company $LLY Shares Sold by FUKOKU MUTUAL LIFE INSURANCE Co - MarketBeat
Lilly unveils supercomputer to expand AI drug discovery push - The Pharma Letter
Close Asset Management Ltd Has $43.54 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly, Nvidia Launch LillyPod: Pharma’s First ‘AI Factory’ in Indianapolis - TipRanks
Navigating Price Competition: Eli Lilly's Strategic Position in the Weight-Loss Drug Market - AD HOC NEWS
1ST Source Bank Sells 983 Shares of Eli Lilly and Company $LLY - MarketBeat
RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market - Finviz
Lilly’s Orforglipron Tops Novo’s Semaglutide In Diabetes Trial - Citeline News & Insights
Friday Five – Novo's no-go week, tolerability tempers Lilly's oral edge, GSK makes pulmonary hypertension play…and more - FirstWord Pharma
Now Live: The World’s Most Powerful AI Factory for Pharmaceutical Discovery and Development - NVIDIA Blog
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 - Benzinga
Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet - Investing News Network
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Latest Research: Eli Lilly and Co's Oral Weight-Loss Drug Orforglipron Demonstrates Superior Weight Loss Effects Compared to Semaglutide Tablets - 富途牛牛
Building permit issued for $77M expansion at Eli Lilly manufacturing campus in Concord - The Business Journals
Eli Lilly and Company GLP-1 pill outperforms rival in type 2 diabetes trial - Traders Union
Eli Lilly's weight-loss pill shows higher side effects than Novo rival in diabetes trial - Reuters
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly Shares Weather Competitive Pricing Move - AD HOC NEWS
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy HQ - Inside INdiana Business
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus - Indianapolis Business Journal
Eli Lilly Prevails in Appeal of Licensor’s Drug Royalty Claim - Bloomberg Law News
9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case - Law360
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics - The Chronicle-Journal
Eli Lilly Strengthens Market Leadership as Rival Stumbles - AD HOC NEWS
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - aol.com
Assessing Eli Lilly: Insights From 13 Financial Analysts - Benzinga
Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market - thestreet.com
Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study - Finviz
Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact - Finviz
Novo Nordisk's Loss Is Eli Lilly's Gain - AOL.com
Bernstein reiterates Eli Lilly stock rating after Novo pricing move By Investing.com - Investing.com Canada
Ozempic Price War - Benzinga
Thoroughbred Financial Services LLC Sells 4,901 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly stock price forecast: Steadies around $1,042 after recent pullback - Traders Union
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,300 - 富途牛牛
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Benzinga
Eli Lilly Strengthens Lead in Weight-Loss Drug Market with New Clinical Data - AD HOC NEWS
Eli Lilly Strengthens Market Lead with Clinical and Commercial Wins - AD HOC NEWS
Intensifying Price War in Weight-Loss Drugs Hits Eli Lilly Stock - Intellectia AI
0.05%
1.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):